China Nuokang Bio-Pharmaceutical Inc. to Report First Quarter 2012 Financial Results
10 Mayo 2012 - 8:00AM
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or
the "Company"), a leading China-based biopharmaceutical company
focused on the research, development, manufacture, marketing and
sales of hospital-based medical products, today announced that the
Company plans to release first quarter 2012 financial results on
Wednesday, May 23, 2012 after the market closes.
The Company will hold a conference call at 8:00 a.m. ET on
Thursday, May 24, 2012 to discuss first quarter 2012 results.
Listeners may access the call by dialing:
United States toll free: |
1-855-500-8701 |
China toll free: |
400-1200654 |
Hong Kong toll free: |
800-903737 |
United Kingdom toll free: |
0800-0159724 |
International: |
65-6723-9385 |
Conference ID: |
78456828 |
A telephone replay will become available beginning two hours
after the conclusion of the call and will remain available through
June 7, 2012. Listeners may access the replay by dialing:
United States toll free: |
1-866-214-5335 |
International: |
61-2-8235-5000 |
Conference ID: |
78456828 |
A webcast will also be available through the Company's website
www.nkbp.com.
About China Nuokang Bio-Pharmaceutical Inc.
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading
biopharmaceutical company in China focused on the research,
development, manufacture, marketing and sales of hospital-based
medical products. The Company provides a diversified portfolio of
products across more than 4,200 hospitals in China. Nuokang's
principal products include Baquting®, China's leading hemocoagulase
product by market share; Kaitong®, a lipid emulsion alprostadil
product for the treatment of peripheral vascular diseases,
cardiocerebral microcirculation disorders and post-surgery
thrombosis; and alpha lipoic acid capsules, or ALA, an antioxidant
product that addresses diabetic neuropathy. The Company's product
pipeline includes product candidates under development in
hematological, cardiovascular and cerebrovascular disease
diagnosis, treatment and prevention. Please visit www.nkbp.com for
more information.
CONTACT: ICR, Inc.
Mr. Rob Koepp
Tel: (+86) 10-6583-7516 or (646) 405-5180
Email: robert.koepp@icrinc.com
China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) (NASDAQ:NKBP)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) (NASDAQ:NKBP)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) (NASDAQ): 0 recent articles
Más de China Nuokang Bio-Pharmaceutical Inc. Artículos de Noticias